Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?

British Journal of Pharmacology

Volumn 164, Issue 5, 2011, Pages 1393-1396

  Kast, R E ^a   Karpel Massler, G ^b   Halatsch, M E ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

AMP kinase; chemotherapy; glioblastoma; metformin; olanzapine; temozolomide

Indexed keywords

6 O METHYLGUANINE; HISTAMINE H1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; METFORMIN; OLANZAPINE; PROTEIN P53; TEMOZOLOMIDE;

APOPTOSIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; EVIDENCE BASED MEDICINE; GLIOBLASTOMA; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BENZODIAZEPINES; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; ENERGY METABOLISM; ENZYME ACTIVATION; GLIOBLASTOMA; HUMANS; METFORMIN;

EID: 80054015235     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01320.x     Document Type: Review

References (35)

1. Altschuler EL, Kast RE, (2005). Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses 65: 65-67. (Pubitemid 40704532)
2. Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, et al,. (2007). Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93: 99-108. (Pubitemid 46839067)
3. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F, (2010). Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9: 1092-1099.
4. Bradding P, Wulff H, (2009). The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol 157: 1330-1339.
5. Cantõ C, Auwerx J, (2010). AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci 67: 3407-3423.
6. Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollõn J, et al,. (2009). Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113: 19-26.
7. Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML, (2008). Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 32: 925-931.
8. Chou CC, Lunn CA, Murgolo NJ, (2008). KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation? Expert Rev Mol Diagn 8: 179-187. (Pubitemid 351469437)
9. Clark RB, Perkins JP, (1971). Regulation of adenosine 3′:5′-cyclic monophosphate concentration in cultured human astrocytoma cells by catecholamines and histamine. Proc Natl Acad Sci U S A 68: 2757-2760.
10. Cohrs S, (2008). Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 22: 939-962.
11. Falus A, (1993). Interleukin-6 biosynthesis is increased by histamine in human B-cell and glioblastoma cell lines. Immunology 78: 193-196. (Pubitemid 23054453)
12. Fioretti B, Catacuzzeno L, Sforna L, Aiello F, Pagani F, Ragozzino D, et al,. (2009). Histamine hyperpolarizes human glioblastoma cells by activating the intermediate-conductance Ca2+-activated K+ channel. Am J Physiol Cell Physiol 297: C102-C110.
13. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al,. (2008). Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199.
14. Hishinuma S, Young JM, (1995). Characteristics of the binding of [3H]-mepyramine to intact human U373 MG astrocytoma cells: evidence for histamine-induced H1-receptor internalisation. Br J Pharmacol 116: 2715-2723.
15. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al,. (2010). Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369-2380.
16. Kast RE, (2010). Profound blockage of CXCR4 signaling at multiple points using the synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct. Turk Neurosurg 20: 425-429.
17. Kast RE, Altschuler EL, (2006). Current drugs available now for interleukin-6 suppression as treatment adjunct in glioblastoma: anakinra, aprepitant, mirtazapine and olanzapine. Int J Cancer Res 2: 303-314. (Pubitemid 46739270)
18. Kast RE, Foley KF, (2007). Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl) 16: 351-354.
19. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH, (2007). From the Cover: Antipsychotic drug induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMPkinase. Proc Natl Acad Sci U S A 104: 3456-3459. (Pubitemid 46364180)
20. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al,. (2011). Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148.
21. Li L, Kracht J, Peng S, Bernhardt G, Buschauer A, (2003). Synthesis and pharmacological activity of fluorescent histamine H1 receptor antagonists related to mepyramine. Bioorg Med Chem Lett 13: 1245-1248. (Pubitemid 36351326)
22. Medina VA, Rivera ES, (2010). Histamine receptors and cancer pharmacology. Br J Pharmacol 161: 755-767.
23. Pereira A, McLaren A, Bell WR, Copolov D, Dean B, (2003). Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow. Pharmacogenomics J 3: 227-34. (Pubitemid 37160978)
24. Rettenbacher MA, Hofer A, Kemmler G, Fleischhacker WW, (2010). Neutropenia induced by second generation antipsychotics: a prospective investigation. Pharmacopsychiatry 43: 41-4.
25. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al,. (2007). Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26: 186-197. (Pubitemid 46095730)
26. Sciaccaluga M, Fioretti B, Catacuzzeno L, Pagani F, Bertollini C, Rosito M, et al,. (2010). CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am J Physiol Cell Physiol 299: C175-C184.
27. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al,. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646. (Pubitemid 41780780)
28. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al,. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
29. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al,. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet. Oncology 10: 459-466.
30. Vassella E, Vajtai I, Bandi N, Arnold M, Kocher V, Mariani L, (2010). Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults. J Neurooncol [Epub ahead of print] PMID: 21181234.
31. Weydt P, Möller T, Labrakakis C, Patt S, Kettenmann H, (1997). Neuroligand-triggered calcium signalling in cultured human glioma cells. Neurosci Lett 228: 91-94. (Pubitemid 27314344)
32. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al,. (2008). Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 165: 352-358.
33. Zadra G, Priolo C, Patnaik A, Loda M, (2010). New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res 16: 3322-3328.
34. Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y, et al,. (2008). Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 173: 545-560.
35. Zhang WB, Wang Z, Su F, Jin YH, Liu HY, Wang QJ, et al,. (2010). Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 285: 40461-40471.